Abbrea Capital LLC Has $439,000 Stake in UnitedHealth Group Incorporated (UNH)

Abbrea Capital LLC maintained its position in UnitedHealth Group Incorporated (NYSE:UNH) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,677 shares of the healthcare conglomerate’s stock at the end of the first quarter. Abbrea Capital LLC’s holdings in UnitedHealth Group were worth $439,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the stock. Penserra Capital Management LLC increased its position in UnitedHealth Group by 285.2% in the first quarter. Penserra Capital Management LLC now owns 2,400 shares of the healthcare conglomerate’s stock valued at $393,000 after buying an additional 1,777 shares in the last quarter. Coldstream Capital Management Inc. purchased a new position in UnitedHealth Group during the first quarter valued at approximately $202,000. Bahl & Gaynor Inc. increased its position in UnitedHealth Group by 3.7% in the first quarter. Bahl & Gaynor Inc. now owns 209,461 shares of the healthcare conglomerate’s stock valued at $34,354,000 after buying an additional 7,389 shares in the last quarter. First National Trust Co. increased its position in UnitedHealth Group by 44.3% in the first quarter. First National Trust Co. now owns 32,022 shares of the healthcare conglomerate’s stock valued at $5,252,000 after buying an additional 9,837 shares in the last quarter. Finally, Tiedemann Wealth Management LLC increased its position in UnitedHealth Group by 188.2% in the first quarter. Tiedemann Wealth Management LLC now owns 7,524 shares of the healthcare conglomerate’s stock valued at $1,234,000 after buying an additional 4,913 shares in the last quarter. Hedge funds and other institutional investors own 86.21% of the company’s stock.

Shares of UnitedHealth Group Incorporated (UNH) traded down 0.6558% during midday trading on Wednesday, reaching $193.2245. The company’s stock had a trading volume of 1,056,509 shares. The stock has a market cap of $186.82 billion, a price-to-earnings ratio of 23.2129 and a beta of 0.64. UnitedHealth Group Incorporated has a 52-week low of $132.39 and a 52-week high of $196.04. The stock has a 50-day moving average price of $189.87 and a 200-day moving average price of $175.41.

UnitedHealth Group (NYSE:UNH) last announced its earnings results on Tuesday, July 18th. The healthcare conglomerate reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.08. UnitedHealth Group had a return on equity of 21.52% and a net margin of 4.32%. The firm had revenue of $50.05 billion during the quarter, compared to analyst estimates of $49.97 billion. During the same quarter in the prior year, the company earned $1.96 EPS. The business’s revenue was up 7.7% compared to the same quarter last year. Equities research analysts anticipate that UnitedHealth Group Incorporated will post $9.87 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 19th. Stockholders of record on Friday, September 8th will be given a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.54%. UnitedHealth Group’s dividend payout ratio is currently 35.13%.

ILLEGAL ACTIVITY NOTICE: This article was first published by [[site]] and is the sole property of of [[site]]. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at [[permalink]].

Several research firms have commented on UNH. Cowen and Company reiterated an “outperform” rating and issued a $220.00 target price (up from $175.00) on shares of UnitedHealth Group in a research report on Friday, August 11th. Zacks Investment Research upgraded UnitedHealth Group from a “hold” rating to a “buy” rating and set a $215.00 target price for the company in a research report on Tuesday, August 1st. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $205.00 price objective (up from $203.00) on shares of UnitedHealth Group in a research report on Friday, July 21st. Sanford C. Bernstein restated an “outperform” rating and set a $210.00 price objective (up from $190.00) on shares of UnitedHealth Group in a research report on Saturday, July 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $208.00 price objective on shares of UnitedHealth Group in a research report on Friday, July 21st. One investment analyst has rated the stock with a hold rating and twenty-four have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $202.20.

In other news, Director Gail R. Wilensky sold 5,540 shares of the stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $178.74, for a total value of $990,219.60. Following the completion of the transaction, the director now owns 60,516 shares of the company’s stock, valued at approximately $10,816,629.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William C. Ballard, Jr. sold 5,000 shares of the stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $193.98, for a total value of $969,900.00. Following the completion of the transaction, the director now directly owns 76,058 shares of the company’s stock, valued at approximately $14,753,730.84. The disclosure for this sale can be found here. Insiders sold a total of 15,540 shares of company stock valued at $2,873,320 in the last three months. Corporate insiders own 0.89% of the company’s stock.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.